Estrogenic side-effects and serum lipid changes were studied in middle-aged men with coronary heart disease during a 6-month period with varying dosage levels of Manvene, a new estrogen analog. Although significant lipid-shifting effects were noted at 5 and 10 mg. daily, these were not comparable with those of 10 mg. of Premarin. Analysis of seattergrams of individual estrogenic and lipoprotein responses of both Manvene-treated and Premarin-treated patients revealed a favorable dissociation of these effects in 5 of the 29 men in the Manvene groups.
THE profound changes in the serum lipids resulting from estrogen administration to men and women with coronary heart disease have been documented in several laboratories. [1] [2] [3] [4] [5] [6] 
RESULTS
The average changes of the C/P ratios in the 4 treatment groups are shown in figure  2 . At 1 month of therapy, both 5 and 10 mg. dosage levels of Manvene and 10 mg. of Premarin had shown similar lowering effects on the C/P ratio. But from the second month the Premarin group showed a sustained decrease, nearly double that of the 5-and 10-mg. Manvene groups. There was a smaller decrease in the 2.5-mg. Manvene shown in a scattergram; the sum of the per- (fig. 6 ). This Premarin/ Manvene "'potency ratio'" of 5 is similar to that of estrone/Maiivenie in terms of the C/P ratio lowering effect in cholesterol-fed chicks, also found to be about 5.10 Comparative studies of different estrogelns using the immature mouse uterus test revealed that Manvene had only 0.3 to 3 per cent of the estrogenie activity of Premarin.'' This relative lack of estrogenicity has not been borne out by the results in men, since the side-effects scores of patients on 5 or 10 mg. of Manvene daily were often similar to those of the 10-mg. Premarin group. The high incidence of estrogenic side-effects in the 50-mg. Manvene group prevented the continuation of this dosage beyond 2 months. Furthermore, when 10 mg. of Manvene daily were given to 10 postmenopausal women for 7 days, comparison of pretreatment and posttreatment Papanicolaou smears showed uniform cornification of the vaginal epithelial cells, indicating an estrogenie effect. A typical sequence is illustrated in figure 7 .
The conventional biologic tests for estrogenie activity have failed to predict the estrogenie potency ratio of Premarin/Manvene in men. It is suggested that the response of the vaginal epithelium of healthy postmenopausal women might be used for the crude estimation of estrogenicity of new lipid-shifting compounds related to the steroidal estrogens before these substances are administered to men. A similar lack of correspondence between estrogeniie potency in human beings and in experimental animals has been reported by Brown and days, showing large polyhedral, cornified vene were required to match the lipid changes produced by 10 iug. of Premarin.
Manvene produced changes similar to those of adequate doses of conventional estrogens in some subjects, while in others these changes were slight. However, significant serum lipid changes with minimal estrogenic side-effects were seen in 5 of the 29 patients. This observation suggests the feasibility of continuing the search for a truly "nonestrogenic" estrogen derivative with maintained lipidmetabolic effects. 
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